Labcorp agrees to buy BioReference assets for $722 million
Labcorp and OPKO Health announced an agreement on October 15 for Labcorp to acquire selected BioReference Health assets. The price is $722 million in cash at closing, subject to a revenue-based adjustment, plus a potential earnout of up to $150 million.[1]
What the agreement covers
The assets include clinical and women’s health testing services, urology and corrections testing businesses, and certain operating assets, including more than 80 patient service centers. BioReference is an OPKO subsidiary.[1]
Labcorp forecasts approximately $250 million in business revenue in the first year after closing. The additional earnout depends on revenue from the 4Kscore Test. Regulatory approvals and customary closing conditions still apply.[1]
What matters for LH and OPK
Analysis.For Labcorp, the question is whether the acquired operations can deliver the forecast revenue and justify the purchase price. For OPKO, the final proceeds depend on the closing adjustment and any earned contingent payment. The earnout should not be treated as guaranteed cash, and the revenue forecast is not a profit forecast.[1]
Sources
- 1.Labcorp joint announcement, October 15, 2026Oct 15, 2026
Prepared with AI assistance. Reviewed by AlphaYou automated editorial review. Report a correction.